sparkstudio / Shutterstock.com
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.725 billion.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Genentech, Seragon, breast cancer, ARN-810, mergers and acquisitions